EUGENEX Biotechnologies is a Swiss-based company specializing in the generation of high-level expression cell lines and processes for commercial manufacturing of novel biopharmaceuticals and biosimilars.

With more than 20 years of experience in mammalian cell culture and process development, EUGENEX Biotechnologies covers the entire drug development chain from cell line to process development for large scale GMP manufacturing. The EUGENEX team also provides clients patent and regulatory expertise in the field of biosimilars.


Based on its unique GeneXpress technology platform consisting of serum-independent CHO host cell lines (CHOSI), proprietary chemically defined cell culture media and powerful tailored expression vectors, EUGENEX Biotechnologies has the necessary competencies to propel your company to new heights.


Our team of highly skilled scientists guarantee outstanding performance in product yield, product quality, and superior easy-to-scale processes. EUGENEX has developed a wide portfolio of stable, high expressing cell lines for the production of over 45 biopharmaceuticals such as monoclonal antibodies, fusion proteins, and enzymes. More than 12 biosimilars derived from EUGENEX’s cell lines and processes have reached the regulated and non-regulated markets.


 Businessmen and businesswomen